In the history of pulmonary hypertension treatment, prostacyclin analogs were once among the most effective vasodilators, but they all faced a common challenge-the inconvenience of intravenous administration and the instability of their chemical properties. The advent of Selexipag API provided an "orally active" solution to this dilemma. It is an orally effective, long-acting non-prostaglandin prostacyclin receptor agonist, and its molecular design itself is a "prodrug"-it is hydrolyzed in vivo by carboxylesterases into an active metabolite, which has a much higher selectivity for prostacyclin receptors than for other prostaglandin receptor subtypes, thereby minimizing off-target effects on the gastrointestinal tract and platelets while dilating pulmonary blood vessels.
🧬Stable molecular configuration of thiophene urea
The core pharmacodynamic unit of the Selexipag API molecule comprises a 2-thiophenecarboxamide structure, an aromatic urea linker backbone, and an alkoxyalkyl side chain. The molecule lacks chiral carbon atoms and does not exhibit stereoracemic isomers. Selective cyclization, ureation coupling, and anaerobic low-temperature recrystallization processes are used to eliminate thiophene oxidation impurities, urea bond hydrolysis amine fragments, and unalkylated intermediates, preventing impurities from interfering with IP receptor binding affinity assays and quantitative detection of pulmonary artery smooth muscle cell proliferation.
If the thiophene aromatic ring is oxidized and destroyed, the molecule cannot embed itself in the hydrophobic binding pocket of the IP receptor, resulting in near-complete loss of receptor agonist activity. After urea bond hydrolysis, the internal hydrogen bond network collapses, making it difficult to maintain the optimal receptor binding conformation. The intact thiophene-aromatic urea-alkoxy side chain conjugated backbone is a crucial prerequisite for the metabolic activation and selective activation of the IP receptor by the Selexipag API. Stable for 24 months when stored in a sealed, dry place protected from light at 2-8℃. Under high temperature and strong alkaline conditions, the urea bond and ester side chain are easily hydrolyzed in aqueous solution. After multiple passages of pulmonary artery smooth muscle cells and simulated incubation with rat plasma, the purified powder molecular skeleton remains intact and does not lyse. The thiophene aromatic ring, urea bond group, and terminal alkoxy side chain are the core functional regions for binding to the IP receptor.
Selexipag API is orally absorbed into the bloodstream. In vivo, esterases hydrolyze the side chain ester groups, converting it into the active metabolite ACT-3336. The thiophene ring occupies the IP receptor ligand binding cavity through hydrophobic interactions. The nitrogen and oxygen atoms of the urea bond form multiple hydrogen bonds with the receptor amino acid residues, stabilizing the receptor's activated conformation and triggering downstream signaling pathways. Once thiophene is oxidized and the urea bond is hydrolyzed, all multiple interactions disappear, and the pulmonary vasodilatory and vascular remodeling inhibitory activities are completely lost.
The polar urea bond group, along with the hydrophobic thiophene and aromatic carbon skeleton, synergistically balances the lipid-water partition coefficient. The urea bond provides polar hydrogen bond sites, allowing for uniform dispersion in oral acidic buffers and cell culture media. The dual aromatic hydrophobic skeleton enhances lipid solubility, enabling rapid penetration of pulmonary vascular smooth muscle cell membranes and accumulation in lung lesions. Highly polar small molecules struggle to penetrate the vascular wall tissue barrier, and highly hydrophobic derivatives tend to accumulate in liver lipid tissue, increasing metabolic burden.
Selexipag API balances lung accumulation efficiency with formulation solubility, making it suitable for large-scale pulmonary artery smooth muscle cell culture and high-throughput prostacyclin receptor subtype screening.
Selexipag API differs from natural prostacyclin and its analogues in its stable chemical structure, high selectivity for IP receptors, and minimal activation of EP series receptors, significantly reducing the risk of systemic adverse reactions. Non-selective prostacyclin agonists broadly activate multiple prostaglandin receptors, easily inducing systemic vasodilatory side effects and interfering with in vitro cell assays. Once urea bonds are hydrolyzed and degraded, the selectivity of molecular receptors disappears, the drug efficacy is greatly reduced, and the deviation of vasodilator test data is significantly amplified.
⚙️Three-layered pathway regulation of pulmonary vascular homeostasis alleviates pulmonary hypertension
In a healthy organism, pulmonary vascular tone maintains a dynamic balance, the proliferation rate of vascular smooth muscle is controlled, there is no excessive fibrosis of the vascular intima, and IP receptors are only physiologically moderately activated. There is no exogenous thienourea small molecule intervention in pulmonary vascular circulation.
When pulmonary hypertension occurs, pulmonary arterioles continuously constrict, vascular smooth muscle proliferates abnormally, and intimal fibrosis leads to vascular luminal narrowing, resulting in a sustained increase in pulmonary vascular resistance and a continuously increasing right ventricular load. Traditional prostacyclin preparations have limited administration methods, poor receptor selectivity, and numerous side effects. Selexipag API with substandard purity contains hydrolytic impurities and cannot be converted into active metabolites, distorting in vitro vascular function test results. Single PDE5 inhibitors only dilate blood vessels and cannot effectively inhibit the vascular remodeling process.
Selexipag API accumulates in pulmonary vascular tissue due to its balanced lipid-water properties and achieves three-layered pulmonary vascular regulation based on its thienourea core structure. The first layer relaxes pulmonary arteriolar smooth muscle: active metabolites selectively activate IP receptors, upregulate intracellular cAMP levels, inhibit calcium ion influx, promote smooth muscle relaxation, and reduce pulmonary vascular resistance. The second layer inhibits abnormal proliferation of vascular smooth muscle, blocks pro-proliferative signal transduction, and inhibits the thickening of the vascular wall. The third layer reduces vascular intimal fibrosis, downregulates the expression of pro-fibrotic factors, and delays pulmonary vascular structural remodeling. Selexipag API is stable when administered orally and has excellent IP receptor selectivity, making it suitable for the development of oral pulmonary hypertension tablets, the investigation of the prostacyclin receptor pathway mechanism, the establishment of a rodent model of pulmonary hypertension, and the research on synergistic therapeutic formulations with endothelin antagonists and PDE5 inhibitors.
Selexipag API only targets the IP receptor-mediated vascular homeostasis pathway and does not randomly activate other prostaglandin receptors such as EP. Broad-spectrum prostaglandin agonists act on a wide range of receptors, inducing systemic vasodilation and interfering with experimental interpretation. Selexipag's target selectivity is clear and controllable, and the experimental system focuses on the single variable of IP receptor signaling, significantly improving the reliability of conclusions in pulmonary vascular pharmacology experiments.
🧫Multi-faceted applications in pharmaceutical research and vascular science
Selexipag API is a standard control material for studying the selective IP receptor agonist mechanism, primarily used for constructing in vitro receptor binding models of pulmonary artery smooth muscle cells and three-dimensional pulmonary vascular organoids. Pulmonary vascular tone and vascular remodeling processes are highly dependent on IP receptor signaling regulation. Leveraging the excellent chemical stability and good oral absorption of Selexipag API, a cell incubation system free from urea bond hydrolysis impurities was formulated to conduct receptor affinity assays, quantitative analysis of cAMP levels, and to establish an IP receptor agonist activity evaluation platform, comparing the selectivity differences of various thienourea derivatives for prostacyclin receptor subtypes.
Selexipag API is widely used in pharmacological studies related to pulmonary hypertension and pulmonary vascular remodeling, and in constructing a limonene-induced pulmonary hypertension rat model. In the pathological model, persistent pulmonary vasoconstriction and excessive smooth muscle proliferation are observed. The active metabolite of Selexipag activates IP receptors, improving vascular lesions. The compensatory changes in vascular cells after long-term administration were observed, leading compounds with low systemic side effects targeting pulmonary vascular function were screened, and the pulmonary hypertension drug screening platform was improved.
It possesses irreplaceable value in the development of intermediates for oral pulmonary vascular targeted active pharmaceutical ingredients (APIs), serving as the core for constructing next-generation long-acting IP receptor agonists. Native Selexipag requires twice-daily dosing; using the Selexipag API thiophene-aromatic urea backbone as the starting building block, modifying the terminal alkoxy side chain optimizes plasma protein binding capacity and prolongs in vivo half-life, developing once-daily long-acting oral APIs, and simultaneously exploring formulations that synergistically reduce pulmonary circulation resistance in combination with PDE5 inhibitors.
The development of novel IP receptor-targeting lead molecules and oral pulmonary arterial hypertension formulations globally uses Selexipag API as the pharmacodynamic benchmark. Various thiophene ring-modified derivatives, pulmonary vascular targeted prodrugs, and selective prostacyclin receptor modulators are compared across studies regarding Selexipag API receptor selectivity, vasodilatory activity, and systemic off-target toxicity. Stable and reproducible cell and animal experimental data make it a universal standard reference for high-throughput screening of thiophene urea IP agonists and efficacy analysis of aromatic urea backbones.
🔬Iterative optimization direction of thiophene ring and urea bond side chain molecules
Modification of the thiophene aromatic ring, aromatic urea linker, and alkoxy side chain is the mainstream approach to Selexipag molecular modification. The original molecule, after entering the bloodstream, distributes systemically, but its accumulation in pulmonary arteriolar lesions is limited, resulting in relatively high dosages. Modification of the thiophene ring terminal, attaching a short-chain targeting group with pulmonary vascular smooth muscle affinity, allows the derivative to accumulate more in pulmonary vascular tissue, activating IP receptors at lower dosages, reducing unnecessary exposure to peripheral blood vessels, and enabling the development of long-acting active pharmaceutical ingredients with low-grade flushing and headache side effects.
Lung tissue microenvironment responsiveness modification is a popular optimization route. Researchers attach esterase-specific cleavable masking groups to the ester sites around diseased pulmonary blood vessels. The prodrug has no receptor agonist activity in normal blood vessels and peripheral tissues; only the diseased pulmonary vascular region is reconstructed for hydrolysis and release of active metabolites, further improving lesion targeting and significantly reducing the risk of systemic prostaglandin-related adverse reactions.
Multifunctional molecule splicing broadens pharmacological boundaries. Late-stage pulmonary hypertension is often accompanied by right ventricular myocardial injury. By covalently splicing the thienourea core framework with cardioprotective and antioxidant fragments, the new molecule activates IP receptors to dilate pulmonary vessels and inhibit vascular remodeling, while simultaneously alleviating right ventricular myocardial stress injury, thus developing a composite lead molecule with dual effects of pulmonary vasodilation and cardioprotection.
Aromatic ring substitution can adjust the therapeutic bias. The original Selexipag achieves a balanced balance of vasodilation and smooth muscle proliferation inhibition, suitable for basic interventions in various types of pulmonary hypertension. Site-specific modification of the thienourea ring substitution sites can prepare derivatives with a focus on acute vasodilation or anti-vascular remodeling. The diastolic subtype is used for adjunctive intervention in acute pulmonary artery pressure elevation, while the anti-proliferative subtype is used for long-term delay of vascular structural lesions, achieving precise subtyping and regulation of pulmonary vascular homeostasis.
Conclusion
Selexipag API is a representative "non-prostaglandin" prodrug of oral prostacyclin receptor agonists. Its pyrazine-amide skeleton, through a carboxylesterase-mediated activation strategy, achieves oral administration while preserving the pulmonary vasodilatory effect of prostacyclin through the high IP receptor selectivity of its active metabolite. For the pharmaceutical raw material industry, high-purity Selexipag API powder with controlled related substances and compliance with pharmacopoeia standards in multiple countries is the material basis supporting its global supply and dosage-controlled formulation production for pulmonary arterial hypertension treatment.
Xi'an Faithful BioTech Co., Ltd. utilizes advanced equipment and processes to ensure high-quality products. Our Selexipag API meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and preferred superior service make us the partner for medical institutions and researchers worldwide. If you require Selexipag API research or production,Please contact us Click email: allen@faithfulbio.com Or WhatsApp: +86 13137770562.
References
- NCATS Inxight Drugs. (n.d.). SELEXIPAG (UNII: 5EXC0E384L). National Center for Advancing Translational Sciences.
- NCI Thesaurus. (2026). Selexipag (Code C103390). National Cancer Institute.
- PDBj. (2025). Selexipag (Drug Name). Protein Data Bank Japan.
- Actelion Pharmaceuticals. (2015). UPTRAVI (selexipag) tablets prescribing information. FDA.
- ScienceDirect. (n.d.). Selexipag. In Pharmacology and Toxicology Topics. Elsevier.
- Adooq Bioscience. (n.d.). Selexipag (NS-304) (Catalog No. A13162).
- MedChemExpress. (n.d.). Selexipag (HY-15583).
- Sigma-Aldrich. (n.d.). Selexipag, ≥98% (HPLC) (Product No. SML2322).